BioVersys to present data on clinical and preclinical pipeline programs at ESCMID Global 2026

Basel, Switzerland. April 15, 2026, 7am CEST.

• Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital infections and preclinical asset BV500 addressing non-tuberculosis mycobacteria (NTM) infections.
• Experts from the UK, Greece and Switzerland to share preclinical insights on BV100’s activity against CRABC on Sunday, April 19, 2026.
• BioVersys’ CEO, Marc Gitzinger, to present at a session exploring how funding and policy priorities shape infectious disease research and antibiotics innovation on Monday, April 20, 2026.
• ESCMID is the premier annual congress of the European Society of Clinical Microbiology and Infectious Diseases. It takes place from April 17 – 21, 2026 in Munich, Germany.

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today its participation in the 36th Congress of the European Society of Clinical Microbiology & Infectious Diseases (ESCMID Global 2026), where it will present the latest preclinical data on its lead clinical asset BV100 (CRABC) and its preclinical asset BV500 (NTM). As part of this leading conference, BioVersys’ CEO, Dr Marc Gitzinger will present at a session on how funding and policy priorities shape infectious disease research and antibiotics innovation.

Dr. Marc Gitzinger, Chief Executive Officer of BioVersys: “To effectively combat antimicrobial resistance, global cross-industry collaboration is of paramount importance. Clinicians, academic researchers, public-private partners, policy makers, and industry need to come together to accelerate innovation and generate robust evidence-based data that will address current and future healthcare requirements. BioVersys is proud to contribute to this collective effort at ESCMID Global 2026, with our key collaborators, by sharing preclinical data on BV100 and BV500. We strongly believe that our products will be integral to the treatment paradigm for some of the current unmet treatment needs in AMR. We will continue to systematically develop our clinical assets towards regulatory approval.”

BV100 is a novel intravenous formulation of rifabutin based on the newly identified mode of action for the active uptake of rifabutin into the Acinetobacter baumannii-calcoaceticus complex (ABC). It is currently being studied in a global Phase 3 clinical trial (RIV-TARGET), with the potential to be a best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). BV100 has Qualified Infectious Disease Product (QIDP) Designation from the U.S. FDA, making BV100 eligible for priority FDA review, Fast Track designation, and a five-year extension of market exclusivity.

BV500 is derived from the company’s proprietary Ansamycin Chemistry platform and a successful collaboration within the SmartLab public-private partnership with the University of Lille (France). BioVersys’ research teams in Lille (France) and Basel (Switzerland) have identified and developed several advanced, highly potent and orally bioavailable Lead candidates, with broad-spectrum in vitro and in vivo anti-NTM activity, which are devoid of cross-resistance with other therapeutic classes. The BV500 program has received funding support and access to key expertise from the CF AMR Syndicate and the EU IHI funded RespiriNTM program. BV500 is under a global research collaboration and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi & Co., Ltd.

Data at a Glance:

• In vitro results suggest BV100 remains active against drug-resistant A. baumannii, including isolates with common rpoB resistance mutations.
• In vitro infection model-based studies show BV100 combinations (with polymyxin B or cefiderocol) can increase bacterial killing and may help limit resistance in tested strains.
• Preclinical data show BV500 Lead compounds are active against non-tuberculous mycobacteria (including M. abscessus) both in vitro and in vivo.

Full PR available here